News and Announcements
The Pulse appoints new Chief Medical Officer
- Published July 11, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Pulse appoints Dr Mark Hohenberg as Chief Medical Officer.
- Dr Hohenberg will head the company’s effort to integrate cutting-edge technologies into the healthcare and education sectors.
The Pulse has announced the appointment of Dr Mark Hohenberg as the Chief Medical Officer. The company aims to deliver world-class communication using technology platforms such as virtual reality (VR) and augmented reality (AR). The appointment of a senior clinician and academic to lead the healthcare technology integration projects is considered an Australian first. Hohenberg, an academic geriatric physician with roles at Campbelltown Hospital and Western Sydney University clinical Dean, will oversee the company’s development and integration of products for the healthcare and health professional education markets.
The decision to join an agency such as The Pulse which focuses on communication is unusual for a healthcare professional. Dr Hohenberg believes that the breakthroughs and efficiency that can be made by technology platforms will be ground-breaking and contribute to healthcare globally. The Pulse and Dr Hohenberg will work to incorporate VR and AR in healthcare to highlight the changing culture towards digitisation for efficiency in healthcare.
About the Pulse IQ
The Pulse IQ is a world first, device-agnostic platform for the delivery of immersive and collaborative Virtual Reality content for training and education.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
